Radiant Biotherapeutics Appoints Deborah Geraghty as President and CEO
核心洞察
Toronto-based biotech company Radiant Biotherapeutics (搜索) has named Deborah Geraghty, Ph.D., as President and Chief Executive Officer to lead the company's next phase of growth.
Dr. Geraghty brings over 20 years of financial, operational, and strategic experience in biopharmaceutical leadership, having previously served as President and CEO of Anokion SA.
The company also appointed Stefan Larson, Ph.D., as Chair of the Board of Directors and Ingmar Bruns, M.D., Ph.D., as Board Member to strengthen its leadership team.
Toronto-based biotech company Radiant Biotherapeutics (搜索) has announced the appointment of Deborah Geraghty, Ph.D., as President and Chief Executive Officer, marking a significant leadership transition for the company. The appointment comes as part of a broader leadership restructuring that also includes new board appointments.
Leadership Appointments
Dr. Geraghty brings over 20 years of financial, operational, and strategic experience leading biopharmaceutical companies to her new role at Radiant Biotherapeutics (搜索). She previously served as President and CEO of Anokion SA, demonstrating her track record in biotechnology leadership.
Alongside Dr. Geraghty's appointment, Radiant Biotherapeutics (搜索) has also named Stefan Larson, Ph.D., as Chair of the Board of Directors, and Ingmar Bruns, M.D., Ph.D., as Board Member. Dr. Larson currently serves on diverse biotech boards including Prilenia Therapeutics (搜索) and Apnimed (搜索), while Dr. Bruns holds the position of Chief Medical Officer at Zentalis.
Strategic Vision
"Dr. Geraghty brings a proven track record of building and transforming innovative biotechnology companies and we are delighted to welcome her to Radiant," said Dr. Larson. "Her deep industry expertise and strategic vision make her the ideal CEO to lead Radiant through this next phase of growth."
The leadership changes signal Radiant Biotherapeutics (搜索)' commitment to advancing its strategic objectives under experienced biotechnology industry executives. The appointments reflect the company's focus on leveraging proven leadership expertise to drive future development and growth initiatives.